ABSTRACT
Background: The COVID-19 pandemic in Nigeria led to a national lockdown that resulted in the suspension of academic activities. Objective(s): To evaluate the impact of the COVID-19 national lockdown on pharmacy students' productivity and their coping strategies. Method(s): This study involved the cross-sectional collection of responses from undergraduate students of six Nigerian schools of pharmacy. Data was collected using a structured, validated questionnaire in the form of Google form. The data was entered into a statistical product and service solutions software (SPSS, version-25) for analysis. Result(s): A total of 808 students responded to the questionnaire. The majority of the students' responses (757, 93.7%) showed that their reading duration had decreased during the lockdown. The most missed variable during the closure by students was 'school life' (303, 37.5%). The use of social media (133, 16.5%) was the most common coping strategy. The majority of the students, 544 (67.3%), agreed to participate in the virtual mode of learning. The cost of data was the main challenge to online learning by the students (288, 36.0%). Conclusion(s): This study shows that the productivity of pharmacy students decreased during the COVID-19 lockdown. Social media and business activities were the most common coping mechanisms of pharmacy students. Pharmacy students were willing to accept virtual learning despite possible challenges. Copyright © 2020, International Pharmaceutical Federation. All rights reserved.
ABSTRACT
This paper presents the Mechanical Ventilator Milano (MVM), a novel intensive therapy mechanical ventilator designed for rapid, large-scale, low-cost production for the COVID-19 pandemic. Free of moving mechanical parts and requiring only a source of compressed oxygen and medical air to operate, the MVM is designed to support the long-term invasive ventilation often required for COVID-19 patients and operates in pressure-regulated ventilation modes, which minimize the risk of furthering lung trauma. The MVM was extensively tested against ISO standards in the laboratory using a breathing simulator, with good agreement between input and measured breathing parameters and performing correctly in response to fault conditions and stability tests. The MVM has obtained Emergency Use Authorization by U.S. Food and Drug Administration (FDA) for use in healthcare settings during the COVID-19 pandemic and Health Canada Medical Device Authorization for Importation or Sale, under Interim Order for Use in Relation to COVID-19. Following these certifications, mass production is ongoing and distribution is under way in several countries. The MVM was designed, tested, prepared for certification, and mass produced in the space of a few months by a unique collaboration of respiratory healthcare professionals and experimental physicists, working with industrial partners, and is an excellent ventilator candidate for this pandemic anywhere in the world.